Clinuvel Appoints New Director, No Securities Held

Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.

Clinuvel Pharmaceuticals Ltd has announced the appointment of Pearl E. Grimes, MD as a director on September 6, 2024. According to the Initial Director’s Interest Notice provided to the ASX, Dr. Grimes currently holds no securities in the company. However, she does have a declared interest as the director of the Vitiligo and Pigmentation Institute of Southern California, which is an administration site for SCENESSE patients.

For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.